St Germain CP, Zhao H, Sinha V, Sanz LA, Chédin F, Barlow JH. Genomic patterns of transcription-replication interactions in mouse primary B cells. Nucleic Acids Res. 2022;50:2051–73.
Google Scholar
Casadei L, de Faria FCC, Lopez-Aguiar A, Pollock RE, Grignol V. Targetable pathways in the treatment of retroperitoneal liposarcoma. Cancers. 2022;14:1362.
Google Scholar
Kyriazoglou A, Pagkali A, Kotsantis I, Economopoulou P, Kyrkasiadou M, Moutafi M, et al. Well-differentiated liposarcomas and dedifferentiated liposarcomas: systemic treatment options for two sibling neoplasms. Cancer Treat Rev. 2024;125:102716.
Google Scholar
Zhou X-P, Xing J-P, Sun L-B, Tian S-Q, Luo R, Liu W-H, et al. Molecular characteristics and systemic treatment options of liposarcoma: a systematic review. Biomed Pharmacother. 2024;178:117204.
Google Scholar
Sanda T, Lawton LN, Barrasa MI, Fan ZP, Kohlhammer H, Gutierrez A, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012;22:209–21.
Google Scholar
Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugène C, Raynal V, et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017;49:1408–13.
Google Scholar
Tan SH, Yam AWY, Lawton LN, Wong RWJ, Young RA, Look AT, et al. TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia. Leukemia. 2016;30:959–62.
Google Scholar
Durbin AD, Zimmerman MW, Dharia NV, Abraham BJ, Iniguez AB, Weichert-Leahey N, et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018;50:1240–6.
Google Scholar
Gryder BE, Yohe ME, Chou H-C, Zhang X, Marques J, Wachtel M, et al. PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability. Cancer Discov. 2017;7:884–99.
Google Scholar
Chen Y, Xu L, Mayakonda A, Huang M-L, Kanojia D, Tan TZ, et al. Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma. Nat Commun. 2019;10:1353.
Google Scholar
Deutzmann A, Sullivan DK, Dhanasekaran R, Li W, Chen X, Tong L, et al. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma. Nat Commun. 2024;15:963.
Google Scholar
van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10:301–9.
Google Scholar
Popay TM, Wang J, Adams CM, Howard GC, Codreanu SG, Sherrod SD, et al. MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor-1. Elife. 2021;10:e60191.
Google Scholar
Lourenco C, Resetca D, Redel C, Lin P, MacDonald AS, Ciaccio R, et al. MYC protein interactors in gene transcription and cancer. Nat Rev Cancer. 2021;21:579–91.
Google Scholar
Li S, Fu J, Walker CJ, Yang J, Bhutani D, Chakraborty R, et al. Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. Blood Adv. 2023;7:2926–37.
Google Scholar
Long H, Hou Y, Li J, Song C, Ge Z. Azacitidine is synergistically lethal with XPO1 inhibitor selinexor in acute myeloid leukemia by targeting XPO1/eIF4E/c-MYC signaling. Int J Mol Sci. 2023;24:6816.
Google Scholar
Gruel N, Quignot C, Lesage L, El Zein S, Bonvalot S, Tzanis D, et al. Cellular origin and clonal evolution of human dedifferentiated liposarcoma. Nat Commun. 2024;15:7941.
Google Scholar
Abeshouse A, Adebamowo C, Adebamowo SN, Akbani R, Akeredolu T, Ally A, et al. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171:950–65.e28.
Google Scholar
Yang L, Chen S, Luo P, Yan W, Wang C. Liposarcoma: advances in cellular and molecular genetics alterations and corresponding clinical treatment. J Cancer. 2020;11:100–7.
Google Scholar
Sun H, Lin D-C, Cao Q, Guo X, Marijon H, Zhao Z, et al. CRM1 inhibition Promotes cytotoxicity in Ewing sarcoma cells by repressing EWS-FLI1-dependent IGF-1 signaling. Cancer Res. 2016;76:2687–97.
Google Scholar
Thirasastr P, Somaiah N. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. Ther Adv Med Oncol 2022; 14: 17588359221081073.
Nair JS, Musi E, Schwartz GK. Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IκB and downregulation of survivin. Clin Cancer Res. 2017;23:4301–11.
Google Scholar
Li Y-Q, Fang Z, Zhang W, Rao G-W, Zheng Q. Targeting XPO1 for fighting relapsed/refractory diseases: the research progress of XPO1 inhibitors. Bioorg Chem. 2025;154:108073.
Google Scholar
Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol. 2016;34:3166–74.
Google Scholar
Alhalabi O, Gouda MA, Milton DR, Momin HA, Yilmaz B, Stephen B, et al. A phase IB trial of selinexor in combination with immune checkpoint blockade in patients with advanced renal cell carcinoma. Cancer Med. 2025;14:e70280.
Google Scholar
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, et al. Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. J Clin Oncol. 2023;41:5400–10.
Google Scholar
Gouda MA, Zarifa A, Yang Y, Stephen B, Gurses SA, Sprenger A, et al. Selinexor (KPT-330) in combination with immune checkpoint inhibition in uveal melanoma: a phase 1B trial. J Immunother Precis Oncol. 2025;8:82–8.
Google Scholar
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, et al. Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial. JCO. 2022;40:2479–90.
Google Scholar
Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, et al. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: results of an open-label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023;168:76–82.
Google Scholar
Lock R, Ingraham R, Maertens O, Miller AL, Weledji N, Legius E, et al. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J Clin Investig. 2016;126:2181–90.
Google Scholar
Nakayama R, Zhang Y-X, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, et al. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016;7:16581–92.
Google Scholar
Garg M, Kanojia D, Mayakonda A, Said JW, Doan NB, Chien W, et al. Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma. Oncotarget. 2017;8:7521–32.
Google Scholar
Zuco V, Pasquali S, Tortoreto M, Brich S, Percio S, Dagrada GP, et al. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. J Exp Clin Cancer Res. 2021;40:83.
Google Scholar
Ou W-B, Zhu J, Eilers G, Li X, Kuang Y, Liu L, et al. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status. Oncotarget. 2015;6:10510–20.
Google Scholar
Zhu Z-C, Liu J-W, Yang C, Zhao M, Xiong Z-Q. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. Cell Death Dis. 2019;10:395.
Google Scholar
Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE, et al. Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185. PLoS ONE. 2015;10:e0137210.
Google Scholar
Besora M, Olmos A, Gava R, Noverges B, Asensio G, Caballero A, et al. A quantitative model for alkane nucleophilicity based on c-h bond structural/topological descriptors. Angew Chem Int Ed Engl. 2020;59:3112–6.
Google Scholar
van Venrooij WJ, van Eenbergen J, Janssen AP. Effect of anisomycin on the cellular level of native ribosomal subunits. Biochemistry. 1977;16:2343–8.
Google Scholar
Wu CC-C, Peterson A, Zinshteyn B, Regot S, Green R. Ribosome collisions trigger general stress responses to regulate cell fate. Cell. 2020;182:404–16.e14.
Google Scholar
Li Y, Yue P, Deng X, Ueda T, Fukunaga R, Khuri FR, et al. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia. 2010;12:848–55.
Google Scholar
Brewer A, Sathe G, Pflug BE, Clarke RG, Macartney TJ, Sapkota GP. Mapping the substrate landscape of protein phosphatase 2A catalytic subunit PPP2CA. iScience. 2024;27:109302.
Google Scholar
Chu J, Qin R, Wang S-J, Wang Q, Wu Q. Integrated single-cell and transcriptomic analysis of bone marrow-derived metastatic neuroblastoma reveals molecular mechanisms of metabolic reprogramming. Sci Rep. 2025;15:28519.
Google Scholar
Patton A, Horn N, Upadhaya P, Sarchet P, Pollock RE, Oghumu S, et al. Targeted transcriptomic analysis of well-differentiated and dedifferentiated liposarcoma reveals multiple dysregulated pathways, including glucose metabolism, TGF-β, and HIF-1 signaling. Front Oncol. 2024;14:1456071.
Google Scholar
Gitareja K, Chelliah SS, Sanij E, Sandhu S, Kang J, Khot A. Ribosome biogenesis and function in cancer: from mechanisms to therapy. Cancers. 2025;17:2534.
Google Scholar
Shan X, Roberts C, Kim EJ, Brenner A, Grant G, Percec I. Transcriptional and cell cycle alterations mark aging of primary human adipose-derived stem cells. Stem Cells. 2017;35:1392–401.
Google Scholar
Bonilauri B, Camillo-Andrade AC, Santos MDM, Fischer JSDG, Carvalho PC, Dallagiovanna B. Proteogenomic analysis reveals proteins involved in the first step of adipogenesis in human adipose-derived stem cells. Stem Cells Int. 2021;2021:3168428.
Google Scholar
Ruan H, Li X, Xu X, Leibowitz BJ, Tong J, Chen L, et al. eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis. Elife. 2020;9:e60151.
Google Scholar
Lama D, Verma CS. Deciphering the mechanistic effects of eIF4E phosphorylation on mRNA-cap recognition. Protein Sci. 2020;29:1373–86.
Google Scholar
